Stockreport

IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc.  (IMNN) 
PDF Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter LAWRENCEVILLE, N.J., April 18, 2024 (GLOBE [Read more]